AstraZeneca’s $39 billion acquisition of Alexion is being investigated by the UK’s Competition and Markets Authority (CMA) to determine if the deal is anti-competitive.

The European Union expects to have received more than a billion doses of Covid-19 vaccines by the end of September from four drugmakers, according to a document presented to EU leaders on Tuesday.

The European Commission called on May 7 on the United States and other major Covid-19 vaccine producers to export what they make as the European Union does, rather than talk about waiving intellectual property rights to the shots.

The European Union on May 6 backed a U.S. proposal to discuss waiving patent protections for Covid-19 vaccines, but drugmakers and some other governments opposed the idea, saying it would not solve global inoculation shortages.

The European Commission is working on legal proceedings against AstraZeneca after the drugmaker cut Covid-19 vaccine deliveries to the European Union, sources familiar with the matter said.

The European Commission granted Amarin Corporation Plc’s fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said on March 30.

Swiss drugmakers Roche and Novartis each won European approval for drugs on March 30 in a sign that the rival Basel-based companies are increasingly competing for the same patients.

EU leaders voiced frustration on March 25 over a massive shortfall in contracted deliveries of AstraZeneca Covid-19 vaccines, as a third wave of infections surged across Europe.

The European Union’s drugs regulator on March 11 approved Johnson & Johnson’s single dose Covid-19 vaccine, as the bloc seeks to speed up a stuttering inoculation campaign and boost its supplies.

Johnson & Johnson told the European Union the company is facing supply issues that may complicate plans to deliver 55 million doses of J&J’s Covid-19 vaccine to the bloc in the second quarter of 2021, an EU official told Reuters.